EA201270653A1 - Антагонист dpи его применение - Google Patents

Антагонист dpи его применение

Info

Publication number
EA201270653A1
EA201270653A1 EA201270653A EA201270653A EA201270653A1 EA 201270653 A1 EA201270653 A1 EA 201270653A1 EA 201270653 A EA201270653 A EA 201270653A EA 201270653 A EA201270653 A EA 201270653A EA 201270653 A1 EA201270653 A1 EA 201270653A1
Authority
EA
Eurasian Patent Office
Prior art keywords
antagonist
conditions
pharmaceutically acceptable
acceptable salt
diseases
Prior art date
Application number
EA201270653A
Other languages
English (en)
Inventor
Джейсон Эдвард Бриттэйн
Кристофер Дэвид Кинг
Брайэн Эндрю Стернс
Original Assignee
ПАНМИРА ФАРМАСЬЮТИКАЛС, ЭлЭлСи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ПАНМИРА ФАРМАСЬЮТИКАЛС, ЭлЭлСи filed Critical ПАНМИРА ФАРМАСЬЮТИКАЛС, ЭлЭлСи
Publication of EA201270653A1 publication Critical patent/EA201270653A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
    • C07C323/59—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton with acylated amino groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/39—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
    • C07C323/40—Y being a hydrogen or a carbon atom
    • C07C323/41—Y being a hydrogen or an acyclic carbon atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Изобретение относится к антагонисту DP, 2-(3-(2-((трет-бутилтио)метил)-4-(2,2-диметилпропиламино)фенокси)-4-метоксифенил)уксусной кислоты или ее фармацевтически приемлемой соли. Кроме того, описаны способы получения антагониста DPили его фармацевтически приемлемой соли. Кроме того, описаны фармацевтические композиции, подходящие для введения млекопитающему, которые содержат антагонист DPили его фармацевтически приемлемую соль, и способы применения фармацевтических композиций для лечения респираторных заболеваний или состояний, аллергических заболеваний или состояний, воспалительных заболеваний или состояний, а также других простагландин D-зависимых или простагландин D-опосредованных заболеваний или состояний.
EA201270653A 2010-01-06 2011-01-05 Антагонист dpи его применение EA201270653A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29280710P 2010-01-06 2010-01-06
PCT/US2011/020264 WO2011085033A2 (en) 2010-01-06 2011-01-05 Dp2 antagonist and uses thereof

Publications (1)

Publication Number Publication Date
EA201270653A1 true EA201270653A1 (ru) 2012-11-30

Family

ID=44306127

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201270653A EA201270653A1 (ru) 2010-01-06 2011-01-05 Антагонист dpи его применение

Country Status (12)

Country Link
US (1) US9688624B2 (ru)
EP (1) EP2521713A4 (ru)
JP (1) JP2013516475A (ru)
KR (1) KR20120115989A (ru)
CN (1) CN102812000A (ru)
AU (1) AU2011203649A1 (ru)
CA (1) CA2782085A1 (ru)
EA (1) EA201270653A1 (ru)
IL (1) IL219987A0 (ru)
MX (1) MX2012007927A (ru)
SG (1) SG182398A1 (ru)
WO (1) WO2011085033A2 (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0913930A2 (pt) * 2008-07-03 2015-10-20 Amira Pharmaceuticals Inc antagonistas de receptores de prostaglandinas d2
KR20120038544A (ko) 2009-07-31 2012-04-23 판미라 파마슈티칼스, 엘엘씨 Ｄｐ2 수용체 길항제의 안과용 약학 조성물
BR112014014558A8 (pt) 2011-12-16 2017-07-04 Atopix Therapeutics Ltd composição farmacêutica, uso de um antagonista de crth2 e de um inibidor de bomba de prótons, e, kit para o tratamento de esofagite eosinofílica
CN108938441A (zh) * 2012-03-21 2018-12-07 宾夕法尼亚大学理事会 用于调节毛发生长的组合物和方法
CN103830194A (zh) * 2014-03-11 2014-06-04 熊妲妮 茚达特罗固体分散体及含有其的药物组合物
US20230078995A1 (en) * 2021-09-16 2023-03-16 Caterpillar Paving Products Inc. Fluid spray system timing control

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5239084A (en) 1990-06-29 1993-08-24 Hoffmann-La Roche Inc. Substituted aminoalkyl biphenyl compounds
US5827868A (en) 1991-10-07 1998-10-27 E. R. Squibb & Sons, Inc. Prostaglandin analogs
US5334598A (en) 1993-03-19 1994-08-02 Merck & Co., Inc. Six-membered ring fused imidazoles substituted with phenoxyphenylacetic acid derivatives
US5565485A (en) 1993-03-19 1996-10-15 Merck & Co., Inc. Biphenyl compounds useful or endothelin antagonists
US5391566A (en) 1993-07-20 1995-02-21 Merck & Co., Inc. Benzimidazolinones substituted with phenoxyphenylacetic acid derivatives
DE19601782A1 (de) 1996-01-19 1997-07-24 Merck Patent Gmbh Chinolin-2-(1H)one
CO4960662A1 (es) * 1997-08-28 2000-09-25 Novartis Ag Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados
EP1087937A1 (en) 1998-06-17 2001-04-04 Du Pont Pharmaceuticals Company Cyclic hydroxamic acids as metalloproteinase inhibitors
US6617351B1 (en) 1998-07-31 2003-09-09 Eli Lilly And Company Amide, carbamate, and urea derivatives
PT1177176E (pt) 1999-04-28 2006-08-31 Aventis Pharma Gmbh Derivados de acidos triarilicos como ligandos de receptores ppar.
DE19937537A1 (de) 1999-08-09 2001-03-08 Gruenenthal Gmbh Substituierte 2-Dialkylaminoalkylbiphenyl-Derivate
ATE315230T1 (de) 1999-08-23 2006-02-15 Bml Inc Verfahren zum identifizieren von prostaglandin d2 rezeptor modulatoren
US20010047027A1 (en) 2000-04-12 2001-11-29 Marc Labelle Prostaglandin D2 receptor antagonists
US6878522B2 (en) 2000-07-07 2005-04-12 Baiyong Li Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2
AU2002302248B2 (en) 2001-05-23 2008-03-06 Merck Frosst Canada Ltd. Dihydropyrrolo[1,2-A]indole and tetrahydropyrido[1,2-A]-indole derivatives as prostaglandin D2 receptor antagonists
CA2452391A1 (en) 2001-07-09 2003-01-23 Axys Pharmaceuticals, Inc. 2-[5-(5-carbamimidoyl-1h-heteroaryl)-6-hydroxybiphenyl-3-yl]-succinic acid derivatives as factor viia inhibitors
EP1435946B8 (en) * 2001-09-14 2013-12-18 Amgen Inc. Linked biaryl compounds
EP1558614B1 (en) 2002-10-30 2010-09-01 Merck Frosst Canada Ltd. Pyridopyrrolizine and pyridoindolizine derivatives
JP2004182657A (ja) 2002-12-04 2004-07-02 Eisai Co Ltd Ｈｄｌレベル上昇促進剤
BR0317591A (pt) * 2002-12-20 2005-11-22 Amgen Inc Composto, sal ou pró-medicamento farmaceuticamente aceitáveis, composição farmacêutica, e, métodos para tratar uma doença ou condição, para modular a função de crth2 e/ou um ou mais outros receptores de pgd2 em uma célula e para modular crth2 e/ou um ou mais outros receptores de pgd2
EP1471057B1 (en) 2003-04-25 2006-01-18 Actimis Pharmaceuticals, Inc. Pyrimidinylacetic acid derivatives useful for the treatment of diseases mediated by CRTH2
RU2006109108A (ru) 2003-10-14 2007-11-20 Оксаген Лимитед (GB) Соединения, обладающие активностью антагонистов crth2 рецепторов
GB0324763D0 (en) 2003-10-23 2003-11-26 Oxagen Ltd Use of compounds in therapy
CA2547430A1 (en) 2003-11-26 2005-06-09 Takeda Pharmaceutical Company Limited Receptor function regulating agent
US7019022B2 (en) 2003-12-15 2006-03-28 Merck Frosst Canada & Co. Substituted tetrahydrocarbazole and cyclopentanoindole derivatives
WO2005100298A1 (en) 2004-04-13 2005-10-27 Merck & Co., Inc. Cetp inhibitors
GB0409921D0 (en) 2004-05-04 2004-06-09 Novartis Ag Organic compounds
GB0415320D0 (en) * 2004-07-08 2004-08-11 Astrazeneca Ab Novel compounds
WO2006018325A1 (en) 2004-08-17 2006-02-23 Galderma Research & Development, S.N.C. Novel biaromatic compounds which activate receptors of ppar type and their use in cosmetic or pharmaceutical compositions
JP2008513511A (ja) 2004-09-21 2008-05-01 アサーシス， インク． Ｃｒｔｈ２受容体拮抗作用を示すベンズイミダゾール酢酸およびこれらの使用
MX2007003336A (es) 2004-09-21 2007-06-05 Athersys Inc Acidos aceticos de indol que muestran antagonismo de receptor crth2 y usos de los mismos.
WO2006052798A2 (en) 2004-11-08 2006-05-18 Merck & Co., Inc. Method of treating pathological blushing
WO2006056854A1 (en) 2004-11-23 2006-06-01 Pfizer Products Inc. Dibenzyl amine compounds and derivatives
GB0510584D0 (en) 2005-05-24 2005-06-29 Novartis Ag Organic compounds
GB0518783D0 (en) 2005-09-14 2005-10-26 Argenta Discovery Ltd Indolizine compounds
EP2407453A1 (en) 2005-09-27 2012-01-18 Shionogi & Co., Ltd. PGD2 receptor antagonist
US8148572B2 (en) 2005-10-06 2012-04-03 Astrazeneca Ab Compounds
ATE545637T1 (de) * 2005-12-15 2012-03-15 Astrazeneca Ab Substituierte diphenylether, -amine, -sulfide und methane zur behandlung von atemwegserkrankungen
PT1976828T (pt) 2005-12-29 2017-03-10 Celtaxsys Inc Derivados de diamina como inibidores de leucotrieno a4 hidrolase
CN101490001A (zh) * 2006-06-09 2009-07-22 Icos股份有限公司 用作dp-2拮抗剂的取代的苯乙酸
RU2463292C2 (ru) * 2006-08-21 2012-10-10 Эррэй Биофарма Инк. Производные 4-замещенной феноксифенилуксусной кислоты
TWI519508B (zh) 2007-06-12 2016-02-01 Achaogen Inc 抗菌劑
EP2173735B1 (en) 2007-07-02 2012-01-11 F. Hoffmann-La Roche AG Imidazole derivatives as ccr2 receptor antagonists
BRPI0817935A2 (pt) 2007-10-01 2015-04-07 Hoffmann La Roche Derivados de biarila
GB0719521D0 (en) 2007-10-05 2007-11-14 Argenta Discovery Ltd Compounds
GB0722203D0 (en) 2007-11-13 2007-12-19 Oxagen Ltd Use of CRTH2 antagonist compounds
GB0722216D0 (en) 2007-11-13 2007-12-27 Oxagen Ltd Use of crth2 antagonist compounds
EP2250161B1 (en) 2008-01-18 2013-10-16 Atopix Therapeutics Limited Compounds having crth2 antagonist activity
US8168678B2 (en) 2008-02-01 2012-05-01 Panmira Pharmaceuticals, Inc. N,N-disubstituted aminoalkylbiphenyl antagonists of prostaglandin D2 receptors
EP2245002A4 (en) 2008-02-01 2011-08-17 Amira Pharmaceuticals Inc AMINOALKYLBIPHENYL ANTAGONISTS N, N 'DISUBSTITUTED FROM D2 RECEPTORS OF PROSTAGLANDIN
WO2009102893A2 (en) 2008-02-14 2009-08-20 Amira Pharmaceuticals, Inc. CYCLIC DIARYL ETHER COMPOUNDS AS ANTAGONISTS OF PROSTAGLANDIN D2 receptors
WO2009145989A2 (en) 2008-04-02 2009-12-03 Amira Pharmaceuticals, Inc. Aminoalkylphenyl antagonists of prostaglandin d2 receptors
BRPI0913930A2 (pt) * 2008-07-03 2015-10-20 Amira Pharmaceuticals Inc antagonistas de receptores de prostaglandinas d2
US8378107B2 (en) 2008-10-01 2013-02-19 Panmira Pharmaceuticals, Llc Heteroaryl antagonists of prostaglandin D2 receptors
WO2010042652A2 (en) 2008-10-08 2010-04-15 Amira Pharmaceuticals, Inc. Heteroalkyl biphenyl antagonists of prostaglandin d2 receptors
WO2010057118A2 (en) 2008-11-17 2010-05-20 Amira Pharmaceuticals, Inc. Heterocyclic antagonists of prostaglandin d2 receptors
US20100173313A1 (en) 2009-01-08 2010-07-08 Amira Pharmaceuticals, Inc. Biomarkers of inflammation
JP2013500979A (ja) 2009-07-31 2013-01-10 パンミラ ファーマシューティカルズ，エルエルシー． Ｄｐ２受容体アンタゴニストの皮膚用製剤
KR20120038544A (ko) 2009-07-31 2012-04-23 판미라 파마슈티칼스, 엘엘씨 Ｄｐ2 수용체 길항제의 안과용 약학 조성물

Also Published As

Publication number Publication date
WO2011085033A3 (en) 2011-11-17
US20130053444A1 (en) 2013-02-28
EP2521713A2 (en) 2012-11-14
SG182398A1 (en) 2012-08-30
MX2012007927A (es) 2012-08-15
CA2782085A1 (en) 2011-07-14
EP2521713A4 (en) 2013-10-02
US9688624B2 (en) 2017-06-27
AU2011203649A1 (en) 2012-06-14
IL219987A0 (en) 2012-07-31
WO2011085033A2 (en) 2011-07-14
KR20120115989A (ko) 2012-10-19
JP2013516475A (ja) 2013-05-13
CN102812000A (zh) 2012-12-05

Similar Documents

Publication Publication Date Title
EA201390840A1 (ru) Полициклический lpaантагонист и его применение
EA201491060A1 (ru) Новые производные трифторметилоксадиазола и их применение для лечения заболевания
EA201490228A1 (ru) Новые производные трифторметилоксадиазола и их применение для лечения заболевания
WO2011017201A3 (en) Dp2 antagonist and uses thereof
EA201101671A1 (ru) Замещенные производные аминопропионовой кислоты в качестве ингибиторов неприлизина
EA201390917A1 (ru) Дигетероарильные соединения в качестве ингибиторов vps34
EA201270653A1 (ru) Антагонист dpи его применение
EA201270824A1 (ru) Соединения для уменьшения продукции бета-амилоида
EA201390969A1 (ru) Модуляторы глюкагонового рецептора
WO2011106729A3 (en) Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents
EA201200318A1 (ru) Гетероциклические оксимы
WO2012116176A3 (en) Asymmetric ureas and medical uses thereof
EA201592255A1 (ru) Производные пиразолопирролидин-4-она в качестве ингибиторов вет и их применение при лечении заболевания
UA109421C2 (uk) Фармацевтична композиція, яка містить ліганди сигма-рецептора
EP2682387A3 (en) C7-fluoro substituted tetracycline compounds
WO2010129057A3 (en) Tetracycline compounds
EA201591957A1 (ru) Производные глутаримидов, их применение, фармацевтическая композиция на их основе, способы их получения
CA2777746A1 (en) Benzoimidazole compounds and uses thereof
EA201391018A1 (ru) Препараты иммуносупрессантов
RU2016104844A (ru) Производные n-мочевино замещенных аминокислот как модуляторы формил-пептидного рецептора
WO2011025982A3 (en) Tetracycline compounds
EA201400067A1 (ru) Новая терапевтическая композиция, содержащая апоморфин в качестве активного ингредиента
JP2011046708A5 (ru)
WO2010132670A3 (en) Pentacycline compounds
EA201001566A1 (ru) Новый класс спиропиперидинов для лечения нейродегенеративных заболеваний